Newly diagnosed AML in older adults: Results for venetoclax

Clinical trial results show a 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts.

from Latest Science News -- ScienceDaily https://ift.tt/2FPDOXL

Comments

Popular posts from this blog

Jared Leto Was Responsible for the "We Live in a Society" Line in the 'Zack Snyder's Justice League' Trailer - /FILM

How to keep Amazon, Apple, and Google from listening to your Alexa, Siri, and Assistant recordings - TechHive

Exclusive: IAEA found uranium traces at Iran 'atomic warehouse' - diplomats - Reuters